AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2022
Mar 10, 2022
30583_dirs_2022-03-10_0426ca06-4655-4d10-8317-d86699dbd8c2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2022-03-08
Reporting Person: FUCHS HENRY J (President, Worldwide R&D)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-08 | Common Stock | A | 12840 | — | Acquired | 119323 | Direct |
Footnotes
F1: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
F2: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return for 2019 through 2021 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
F3: Although earned, the RSUs only vest according to the following schedule: 100% vests on March 15, 2022, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.